{
    "organizations": [],
    "uuid": "6e2c04e708a3cf080fa0d4cbe581634dfc70aab6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-formycon-says-biosimilar-candidate/brief-formycon-says-biosimilar-candidate-fyb201-shows-efficacy-comparable-to-reference-product-in-phase-iii-study-idUSFWN1S9015",
    "ord_in_thread": 0,
    "title": "BRIEF-Formycon Says Biosimilar Candidate FYB201 Shows Efficacy Comparable To Reference Product In Phase III Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - Formycon AG:\n* BIOSIMILAR CANDIDATE FYB201 SHOWS EFFICACY COMPARABLE TO REFERENCE PRODUCT IN PHASE III STUDY Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-02T13:05:00.000+03:00",
    "crawled": "2018-05-03T11:48:01.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "formycon",
        "ag",
        "biosimilar",
        "candidate",
        "fyb201",
        "show",
        "efficacy",
        "comparable",
        "reference",
        "product",
        "phase",
        "iii",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}